{'fraction_non_alphanumeric': 0.0350609756097561, 'fraction_numerical': 0.006097560975609756, 'mean_word_length': 5.378640776699029, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Shaking Up the Debate: Ensuring the Ethical Use of DBS Intervention Criteria for Mid‐Stage Parkinson's Patients

Deep brain stimulation (DBS) is a well‐established treatment for the management of severe motor fluctuations in advanced Parkinson's disease (PD). Until recently, device regulation, medical, and insurance practices limited DBS to patients with advanced stages of PD. In February 2016 this changed, however, when the US Food and Drug Administration (FDA) granted formal approval for the use of brain stimulator in mid‐stage PD patients. In this article, we examine whether DBS in mid‐stage PD can be ethically justified beyond the FDA approval.